Regeneron says its COVID-19 antibody cocktail helps prevent symptomatic COVID-19

12/04/2021 7:21:00 PM

New Phase 3 trial data finds a single shot of Regeneron's COVID-19 antibody cocktail was able to prevent symptomatic COVID-19 among people exposed to the virus, the company said.

New Phase 3 trial data finds a single shot of Regeneron's COVID-19 antibody cocktail was able to prevent symptomatic COVID-19 among people exposed to the virus, the company said.

New Phase 3 trial data finds a single shot of Regeneron's COVID-19 antibody cocktail was able to prevent symptomatic COVID-19 among people exposed to the virus, the company said.

(CNN) --New Phase 3 trial data finds a single shot of Regeneron's COVID-19 antibody cocktail was able to prevent symptomatic COVID-19 among people exposed to the virus, the company said Monday.Regeneron said it will seek expansion of the emergency use authorization for the drug, which is currently available in the United States to treat mild-to-moderate COVID-19 in people already infected with the coronavirus.

In the new trial, the drug, named REGEN-COV, reduced risk of symptomatic infections by 81%, the company said Monday in a news release. The trial studied Regeneron's combination of casirivimab with imdevimab in 1,505 people who had not been infected with coronavirus but lived in the same household as someone who tested positive in the four days before. Each participant received one dose of the drug or a placebo, which does nothing, administered as an injection through the skin.

Read more:
CNN Philippines »

Marcos adviser Paul Soriano wants to reach out to critics: ‘I choose to see the good’

‘For me, if we can support our president it just means that our country will be better,’ says the newly-appointed presidential adviser. Not all may agree, however. Read more >>

investing with maria D bate was the best thing that have ever happened to me cause I ear u p to $5000 with $400 through forex trading she's the best I know of , after I was scammed , thanks very much mam . well if you are interested click and message her 👇👇👇 mariadbates2

PH records 9,661 new COVID-19 cases and nearly 23,000 new recoveriesBREAKING: The Department of Health announces 145 COVID19 deaths, more than 100 for the 4th straight day. The number of active cases is the lowest since March 23 as DOH reports thousands of recoveries daily for one whole week. | via EdsonCGuido READ: EdsonCGuido Nice!! 22K Recoveries!!! ( hope its true) EdsonCGuido Grabe ung mass healing today ha. 22k sana talaga totoo. EdsonCGuido Naniniwala kayo sa almost 1M na nagka covid pero sa 22k na recoveries hindi?eh same source lang din naman tinitignan nyo.,

Thailand reports 11 new COVID-19 deaths, new daily record for second dayThailand reported 2,438 new coronavirus cases and 11 new deaths, bringing the total number of infections to 55,460 and fatalities to 140 since the pandemic started last year. 😢😢 God bless Thailand!

DFA reports 7 new COVID-19 recoveries among Filipinos abroad; no new cases and deathsSeven Filipinos abroad who have contracted COVID-19 have recuperated, bringing total recoveries among the group to 11,149, the Department of Foreign Affairs said on Monday.

PH logs 10,098 new COVID-19 cases, more than 72,000 new recoveriesThe Philippines on Sunday reported 72,607 additional recoveries, the highest reported in a day, according to the ABS-CBN Data Analytics Team, bringing the total number of people who have recuperated from the infectious disease to 779,084. Are all those recoveries being tested before declaring them as recovered? A friend of my cousin was declared as recovered, but was not tested. Good thing she did not leave the isolation cause she requested to be tested and turns out she is still positive. Wow. Holy smokes that's bad.

19 additional COVID-19 deaths reported in BulacanThe Provincial Health Office (PHO) in Bulacan on Wednesday reported 19 new deaths due to COVID-19, bringing the total number of deaths in the province to 586 since the start of the pandemic last year.

endIndex: (CNN) -- New Phase 3 trial data finds a single shot of Regeneron's COVID-19 antibody cocktail was able to prevent symptomatic COVID-19 among people exposed to the virus, the company said Monday.Saturday's fresh infections pushed the country's overall tally to 989,380 with 89,485 remaining active cases.BANGKOK - Thailand on Sunday set a record for the daily number of COVID-19 deaths for the second consecutive day, as authorities step up the response to a rapid third wave of infections after about a year of relative success slowing the spread of coronavirus.MANILA - Total cases remained at 18,141, and the death toll at 1,115 as no new infection and fatality were recorded.

Regeneron said it will seek expansion of the emergency use authorization for the drug, which is currently available in the United States to treat mild-to-moderate COVID-19 in people already infected with the coronavirus. In the new trial, the drug, named REGEN-COV, reduced risk of symptomatic infections by 81%, the company said Monday in a news release.  The day's active cases is drastically lower from last Saturday's record-high 203,000 as the DOH reported thousands of new recoveries daily this week, veering away from weekly "mass recoveries" every Sunday. The trial studied Regeneron's combination of casirivimab with imdevimab in 1,505 people who had not been infected with coronavirus but lived in the same household as someone who tested positive in the four days before.617 variant, said Taweesin Wisanuyothin, a spokesman for the government's COVID-19 taskforce. Each participant received one dose of the drug or a placebo, which does nothing, administered as an injection through the skin.3 percent of the country's total recorded cases. After 29 days, 11 people who received a single 1,200 mg dose of the treatment developed symptomatic COVID-19; 59 people who received a placebo developed symptomatic COVID-19.@teddyboylocsin #DFAForgingAhead#WeHealAsOne pic.

The drug provided 72% protection against symptomatic infections in the first week and 93% protection in subsequent weeks, Regeneron said.  This is the 4th straight day that new deaths counted more than 100. Authorities in the capital city of Bangkok have ordered the closure of venues including parks, gyms, cinemas and day-care centers from April 26 through May 9. The data has not yet been peer reviewed or published. Those who received the antibody cocktail and experienced a symptomatic infection resolved their symptoms in one week, the company said, compared to three weeks among those who received a placebo.  As of April 22, around 1,612,420 doses of COVID-19 vaccines have been administered out of the 3,025,600 vaccines distributed across LGUs. "Despite standard precautions to reduce transmission, nearly 10% of unvaccinated individuals living with an infected person developed symptomatic infections if they did not receive REGEN-COV," Dr.1. Myron Cohen, who leads the monoclonal antibody efforts for the COVID Prevention Network and is the director of the Institute for Global Health and Infectious Diseases at the University of North Carolina at Chapel Hill, said in a statement.   More details to follow. Data from US-based Johns Hopkins University showed that more than 141 million people globally have contracted COVID-19, with the United States, Brazil, India, France, and Russia leading countries with the most number of cases.

"If authorized, convenient subcutaneous administration of REGEN-COV could help control outbreaks in high-risk settings where individuals have not yet been vaccinated, including individual households and group living settings." Adverse events occurred in 20% of patients who received the antibody drug and 29% of those who received a placebo, Regeneron said. The rising figures have prompted concern over the number of hospital beds, particularly as government policy is to admit anyone testing positive for the novel coronavirus, even those without symptoms. None of the participants who received the drug were hospitalized or went to the ER because of COVID-19 over the course of 29 days; four in the placebo group did so. None of the four deaths in the trial -- two among those who received the drug and two who received a placebo -- were due to COVID-19 or the drug. Regeneron said it will request an expansion of its US Food and Drug Administration emergency use authorization to include COVID-19 prevention and as a subcutaneous shot.  Watch more in iWantTFC.

The drug is currently authorized to be administered as an IV, which takes longer and may be part of the reason why uptake of the treatment has been limited. The company also announced Monday that a second Phase 3 trial studied an injection of its antibody cocktail in 204 asymptomatic people recently infected with the coronavirus. A single shot reduced the risk of progressing to symptomatic COVID-19 by 31% overall. After the third day, risk was reduced by 76%. Participants received the treatment or a placebo, and the trial showed that the duration of symptoms was shortened and viral levels were reduced in those who received the antibody cocktail.

Eli Lilly and Company previously announced its monoclonal antibody therapy, bamlanivimab, helped prevent symptomatic Covid-19 infection among nursing home residents and staff. However, the US government said last month it will no longer distribute bamlanivimab for use on its own because of a sustained increase in coronavirus variants in the United States. Bamlanivimab can still be used with etesevimab, another monoclonal antibody treatment developed by Eli Lilly; in combination, the two Eli Lilly treatments seem to work against coronavirus variants. So far, Regeneron's cocktail has been shown to be effective against coronavirus variants of concerns. This story was first published on CNN.

com, .